Global Human Insulin Market 2015-2019


◆タイトル:Global Human Insulin Market 2015-2019
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:pdf / 英語
Single UserUSD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。





About diabetes
Insulin is a hormone produced by beta cells of the pancreas that plays a key role in the regulation of blood glucose levels. It controls the body systems and regulates the uptake of amino acids by body cells. It helps cells absorb glucose from the blood. In diabetics, cells stop responding to the insulin produced. As a result, glucose in the blood cannot be absorbed by the cells of the body. This condition damages body tissues over the period of time and causes disabling and life-threatening health complications such as diabetic nephropathy and diabetic retinopathy. In type 1 diabetes, the body does not produces sufficient insulin to regulate blood glucose level. Individuals with this type of diabetes need to take insulin daily. Patients with type 2 diabetes also need doses of insulin coupled with medication. Different types of insulin such as human insulin and insulin analogs are available as insulin replacement therapy.

Technavio’s analysts forecast the global human insulin market to grow at a CAGR of 10.29% over the period 2014-2019.

[Covered in this report]
The report includes the present scenario and the growth prospects of the global human insulin market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of diabetes.

Technavio’s report, Global Human Insulin Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report includes a discussion of the key vendors operating in this market.

[Key vendors]
• Eli Lilly
• Novo Nordisk
• Sanofi

[Other prominent vendors]
• Biocon
• Biodel
• Biogenomics
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Diamyd Medical
• Diasome Pharmaceuticals
• DiaVacs
• Pfizer
• Generex Biotechnology
• Lexicon Pharmaceuticals
• Macrogenics
• Merck
• Oramed Pharmaceuticals
• Osiris Therapeutics
• Thermalin Diabetes
• Tolerion
• Wockhardt
• XOMA Corporation

[Market driver]
• Increase in prevalence of diabetes
• For a full, detailed list, view our report

[Market challenge]
• Stringent regulatory environment
• For a full, detailed list, view our report

[Market trend]
• Increasing R&D for novel mechanisms
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?


PART 01: Executive summary

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Product profiles

PART 04: Market research methodology
Research methodology
Economic indicators

PART 05: Disease overview

PART 06: Pipeline analysis

PART 07: Introduction
Key market highlights

PART 08: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 09: Market segmentation by type of insulin
Fast-acting insulin
Intermediate-acting insulin
Long-acting insulin

PART 10: Market segmentation by type of disease

PART 11: Geographical segmentation

PART 12: Market drivers

PART 13: Impact of drivers

PART 14: Market challenges

PART 15: Impact of drivers and challenges

PART 16: Market trends

PART 17: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors

PART 18: Key vendor analysis
Novo Nordisk

PART 19: Appendix
List of abbreviation

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Diabetes prevalence rate in various countries (2000 and 2030)
Exhibit 03: Global human insulin market 2014-2019 ($ Billions)
Exhibit 04: Five forces analysis
Exhibit 05: Global human insulin market by type of disease 2014
Exhibit 07: Global human insulin market segmentation by geography 2014
Exhibit 08: Impact of drivers
Exhibit 09: Impact of drivers and challenges
Exhibit 10: Novo Nordisk: Company strategy
Exhibit 11: Modern insulins: Drug sales 2010-2014 ($ millions)
Exhibit 12: NovoRapid/NovoLog: Drug sales 2010-2014 ($ millions)
Exhibit 13: Levemir: Drug sales 2010-2014 ($ millions)
Exhibit 14: NovoMix: Drug sales 2010-2014 ($ millions)
Exhibit 15: Human insulins: Drug sales 2010-2014 ($ millions)
Exhibit 16: Sanofi: Company strategy
Exhibit 17: Lantus: Drug sales 2010-2014 ($ millions)
Exhibit 18: Apidra: Drug sales 2010-2014 ($ millions)
Exhibit 19: Insuman: Drug sales 2010-2014 ($ millions)
Exhibit 20: Lilly: Company strategy
Exhibit 21: Humalog: Drug sales 2010-2014 ($ millions)
Exhibit 22: Humulin: Drug sales 2010-2014 ($ millions)
Exhibit 23: Novo Nordisk: R&D expenditure 2014


Lilly, Novo Nordisk, Sanofi, Biocon, Biodel, Biogenomics, Boehringer Ingelheim, Bristol-Myers Squibb, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Pfizer, Generex Biotechnology, Lexicon Pharmaceuticals,Macrogenics, Merck, Oramed Pharmaceuticals, Osiris Therapeutics, Thermalin Diabetes, Tolerion, Wockhardt, XOMA